CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 36 enrolled
Drug / intervention
salmeterol +2 moredrug
Likely dose
Salmeterol 50 mcg twice per day via diskus inhalerAI-extracted
Key inclusion· 4
  • ✓Age 18-55 years
  • ✓Asthma symptoms for at least 6 months
  • ✓FEV1 greater than 75% of predicted
  • ✓Positive prick skin test to cat, house dust mite, or ragweed
Key exclusion· 4
  • ✕History of life-threatening asthma or anaphylaxis
  • ✕Current smoker
  • ✕Pregnant or breast-feeding
  • ✕Evidence of upper respiratory infection within 4 weeks of screening

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00214019
NCT00214019N/ACompleted
CompareCT.gov

The Effect of Salmeterol on Eosinophil (EOS) Function

University of Wisconsin, Madison·interventional·Posted Sep 21, 2005·Updated Nov 21, 2017

In Brief

A clinical study evaluating salmeterol, Fluticasone, and 1 other intervention for Allergic Asthma. Completed, enrolled 36 participants across 1 site.

Detailed Summary

This study is designed to test the hypothesis that salmeterol use, and not fluticasone use or the combination treatment with fluticasone and salmeterol, is associated with a greater number of sputum eosinophils following antigen challenge and, under these circumstances, the migrating peripheral blood eosinophils are less adherent.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Asthma
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 21, 2005
Enrollment StartNov 1, 2003
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 20.8 years ago

Interventions

salmeteroldrug

salmeterol diskus 50 mcg twice per day

Fluticasonedrug

placebo diskus, fluticasone MDI 88 mcg twice per day

Placebodrug

placebo diskus